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Abstract
Background: High-throughput screening is used by the pharmaceutical industry for identifying
lead compounds that interact with targets of pharmacological interest. Because of the key role that
aberrant regulation of protein phosphorylation plays in diseases such as cancer, diabetes and
hypertension, kinases have become one of the main drug targets. With the exception of antibody-
based assays, methods to screen for specific kinase activity are generally restricted to the use of
small synthetic peptides as substrates. However, the use of natural protein substrates has the
advantage that potential inhibitors can be detected that affect enzyme activity by binding to a site
other than the catalytic site. We have previously reported a non-radioactive and non-antibody-
based fluorescence quench assay for detection of phosphorylation or dephosphorylation using
synthetic peptide substrates. The aim of this work is to develop an assay for detection of
phosphorylation of chemically unmodified proteins based on this polymer superquenching
platform.
Results:  Using a modified QTL Lightspeed™ assay, phosphorylation of native protein was
quantified by the interaction of the phosphorylated proteins with metal-ion coordinating groups
co-located with fluorescent polymer deposited onto microspheres. The binding of phospho-
protein inhibits a dye-labeled "tracer" peptide from associating to the phosphate-binding sites
present on the fluorescent microspheres. The resulting inhibition of quench generates a "turn on"
assay, in which the signal correlates with the phosphorylation of the substrate. The assay was tested
on three different proteins: Myelin Basic Protein (MBP), Histone H1 and Phosphorylated heat- and
acid-stable protein (PHAS-1). Phosphorylation of the proteins was detected by Protein Kinase Cα
(PKCα ) and by the Interleukin -1 Receptor-associated Kinase 4 (IRAK4). Enzyme inhibition yielded
IC50 values that were comparable to those obtained using peptide substrates. Statistical parameters
that are used in the high-throughput community to determine assay robustness (Z'-value)
demonstrate the suitability of this format for high-throughput screening applications for detection
of inhibitors of enzyme activity.
Conclusion: The QTL Lightspeed™ protein detection system provides a simple mix and measure
"turn on" assay for the detection of kinase activity using natural protein substrates. The platform is
robust and allows for identification of inhibitors of kinase activity.
Published: 31 May 2005
BMC Biotechnology 2005, 5:16 doi:10.1186/1472-6750-5-16
Received: 01 March 2005
Accepted: 31 May 2005
This article is available from: http://www.biomedcentral.com/1472-6750/5/16
© 2005 Rininsland et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2005, 5:16 http://www.biomedcentral.com/1472-6750/5/16
Page 2 of 6
(page number not for citation purposes)
Background
Approximately 75% of the drugs in clinical use elicit their
pharmacological effects by interactions with receptor or
enzyme targets, such as kinases [1,2]. Methods to screen
large chemical libraries for inhibitors of protein kinases
include radiometric assays [3], ELISA [4], ATP consump-
tion assays [5] and several fluorescence based assays such
as time-resolved fluorescence (TRF) [6], fluorescence
polarization (FP) [7,8], fluorescence energy transfer
(FRET) [9] or fluorescence quench assays [10]. Assays such
as FRET, FP and fluorescence quench do not require anti-
bodies or radioactive label, and are thus attractive for HTS.
However non-antibody based FP and FRET assays are
restricted to the use of small, synthetic peptide substrates
to monitor kinase activity. While peptide substrates are
convenient for HTS purposes, those that bind with high
affinity are available for only a small percentage of the
>500 kinases encoded by the human genome [11]. Addi-
tionally, peptide substrates may diminish the ability to
detect inhibitors that bind to docking sites of a native pro-
tein substrate or that bind to unique conformational
states induced by protein substrate binding [12]. Here we
report the detection of phosphorylation of the natural
protein substrates Myelin Basic Protein (MBP), Histone
H1 and Phosphorylated heat- and acid-stable protein
(PHAS-1) by PKCα  and IRAK4 using a modified version of
our original assay format [13,14], which is based on
superquenching of fluorescent polyelectrolytes [15,16].
The assay principle is shown in Figure 1.
Phosphorylated protein binds to the QTL Sensor via specific phosphate binding to metal coordinating ions and inhibits the  association of the dye-labeled phosphopeptide (tracer; red "starburst") Figure 1
Phosphorylated protein binds to the QTL Sensor via specific phosphate binding to metal coordinating ions and inhibits the 
association of the dye-labeled phosphopeptide (tracer; red "starburst"). The resulting increase in fluorescence signal correlates 
with the extent of protein phosphorylation.BMC Biotechnology 2005, 5:16 http://www.biomedcentral.com/1472-6750/5/16
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Results
MBP, Histone H1 and and PHAS-1 proteins were phos-
phorylated with PKCα  and IRAK4 as described in the
Methods section. The proteins were used in their native
form and were not chemically modified. An enzyme con-
centration-dependent increase in phosphorylation corre-
lated with increasing fluorescence signal, demonstrating
the efficacy of the QTL Lightspeed™ platform for detection
of phosphorylated proteins (Figure 2). The detection of
MBP phosphorylation worked equally well for protein
substrates derived from either bovine or human (not
shown). In order to explore the utility of the assay for
screening inhibitors, the ATP competitor Staurosporine
was used to inhibit enzyme activities using substrates His-
tone H1, PHAS-1 (Figure 3A) MBP (Figure 3B). For each
protein, a concentration of Staurosporine which inhibited
enzyme activity by 50% (IC50) was determined to be
within the range of the reported value using a peptide sub-
strate (9 nM) [17]: values of 3.8 nM, 1.6 nM and 0.6 nM
were obtained for MBP, Histone H1 and PHAS-1, respec-
tively (Figure 3). The IRAK4 protein assay was 3-fold more
sensitive than a QTL Lightspeed™ assay performed on a
peptide substrate (EC50 = 1.4 nM vs 5 nM). Using MBP as
substrate, we were able to obtain IC50 values for Stau-
rosporine of 11.5 nM, which were very similar to those
obtained using a peptide substrate (19 nM, not shown).
The robustness of the assay (Z') was determined by per-
forming 10 multiples of phosphorylation reactions using
identical assay conditions. The Z' is a statistical parameter
used in the drug screening community to evaluate and val-
idate performance of assays [18]. An assay that delivers a
Z' of higher than 0.5 is considered to be robust. The Z' was
determined using the following equation:
For MBP, high Z' values of 0.84 and 0.8 were obtained for
phosphorylation using PKCα  and IRAK4, respectively. For
PHAS-1 the values were 0.52 and for Histone H1 0.43.
Table 1 summarizes the statistical values obtained for the
three different substrates.
Discussion
Despite the existence of several different technologies to
monitor phosphorylation reactions of kinases, the detec-
tion of protein substrate phosphorylation has been lim-
ited to antibody-based assays, radioactive assays or assays
that measure ATP consumption rather than specific kinase
activity. Antibody-based assays are restricted to available,
purified antibodies, usually directed against phosphoser-
ine and phosphothreonine residues and may have low
affinity and be specific to only a single kinase. Due to
safety concerns over radioisotope handling as well as cost,
drug screening efforts are rapidly moving toward non-
radioactive and non-antibody-based assays. FP fulfills
these criteria. However, since FP signal is correlated with
Enzyme concentration curve using proteins as substrates Figure 2
Enzyme concentration curve using proteins as substrates. MBP (0.5 µg/well) was phosphorylated using various 
amounts of PKCα  and IRAK4 (2A) and Histone H1 and PHAS-1 (0.5 µg/well) were phosphorylated using various amounts of 
PKCα  (2B) for 1 hour at room temperature (~25°C) in a 384-well white Optiplate. Following reaction, QTL Sensor was added 
for 10 minutes at ~25°C. Then, dye-labeled phosphopeptide tracer was added with a final concentration of 0.5 µM for detec-
tion of phosphorylation of MBP or 125 nM for Histone H1 and PHAS-1. The plate was incubated for an additional 30 minutes 
at ~25°C and fluorescence measured.
Z’= 1-
(3 x   max RFU) + ( 3 x   min RFU)
|mean of max RFU -
σσ
   mean min RFU|BMC Biotechnology 2005, 5:16 http://www.biomedcentral.com/1472-6750/5/16
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changes in molecular rotation rates within the fluores-
cence life time and since only molecules smaller than
approximately 20 kDa show significant rotation within
this range most protein substrates are not directly measur-
able by FP [19]. A prompt fluorescence quench assay relies
upon the binding of a phosphate coordinating metal ion
to the phosphate group on a substrate, which is labeled
with a dye [10]. Upon association of the metal ion, fluo-
rescence is quenched. Similar to FRET assays, the rapid
drop in signal with increasing distance between donor
and acceptor molecules makes such assays unsuitable for
the detection of protein phosphorylation, even if the pro-
teins could be labeled with appropriate dyes [9]. The QTL
Lightspeed™ protein assay is a novel non-radioactive and
non-antibody-based assay that follows a simple mix and
measure protocol for the quantitative detection of protein
phosphorylation. Unmodified proteins can be used as
substrates, thus allowing for the integrity of protein struc-
ture, which may be a requirement for successful recogni-
tion and phosphorylation by kinases. Our experiments
utilized 0.5 µg MBP for phosphorylation by PKCα  and
IRAK4, thus moving the assay into the realm of HTS with
regard to cost effectiveness. In this report, we describe the
use of relatively small proteins MBP and PHAS-1 (18.9
kDa and 21 kDa respectively) and show feasibility for the
larger protein Histone H1 (32 kDa) as well. Since our
assay does not rely on site-specific antibodies, the phos-
phorylation of serine, threonine and tyrosine residues is
possible.
Conclusion
We demonstrate that a modified version of our QTL Light-
speed™ platform provides a simple and robust assay for
monitoring protein phosphorylation. The platform does
Staurosporine inhibition of enzyme activity Figure 3
Staurosporine inhibition of enzyme activity. A concentration of 8.6 nM PKCα  was used to phosphorylated Histone H1 
or PHAS-1 for 60 minutes at ~25°C using various concentrations of Staurosporine (3A). Inhibition of PKCα  and IRAK4 activi-
ties using MBP as a substrate were performed using decreasing concentrations of Staurosproine (3B). Following incubation, 
QTL Sensor was added and incubated for 10 minutes at ~25°C. Subsequently dye-labeled phosphopeptide tracer was added 
with a final concentration of 0.5 µM for MBP or 125 nM for Histone H1 and PHAS-1. The plate was incubated for an additional 
30 minutes at ~25°C and fluorescence measured.
Table 1: QTL Lightspeed™ Protein Assay Statistical Data18. Statistics are shown for Z' Factor, signal/noise (S/N), signal/background (S/
B), signal window (SW) and coefficient of variation (% CV) at maximal substrate phosphorylation. Z'Factor equal to or greater than 
0.5 are an indication of a robust assay18. Ten replicate measurements were made to determine the assay statistics.
Protein Enzyme Z' Factor S/N S/B SW %CV
MBP PKCα 0.84 20.7 2.6 33.4 2.2
MBP IRAK4 0.80 23 2.6 31 4.3
PHAS-1 PKCα 0.52 9.6 0.7 9.6 2.8
Histone H1 PKCα 0.43 7.32 0.7 9.4 3.0BMC Biotechnology 2005, 5:16 http://www.biomedcentral.com/1472-6750/5/16
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not employ radioactive labels or antibodies, which makes
it specific as well as time and cost-effective. We show that
the assays for PKCα  are suitable for drug compound
screening by obtaining IC50  values of an ATP-analog
which are very close to those reported in the literature for
this compound. For IRAK4, reported values were not
available. Thus, it is reasonable that our assay is also well-
suited for the identification of inhibitors that are not ATP-
site directed competitors. Further applications of the assay
could be the detection of autophosphorylated kinases or
other proteins that play a role in cell signaling. Finally, the
QTL Lightspeed™ platform can be used to further identify
novel protein substrates for specific kinases.
Methods
Fluorescent poly-phenylene ethyneylene was synthesized
and coated onto microspheres as previously described
[13,14].
Bovine substrate MBP was purchased from Upstate (Char-
lottesville, VA). PHAS-1 was purchased from Biomol (Ply-
mouth Meeting, PA) and Histone H1 from Upstate. The
phosphopeptide tracer was a 13 amino acid peptide,
which was N-terminal labeled with a rhodamine deriva-
tive. The enzyme PKCα  was purchased form Biomol and
IRAK4 from Upstate. The inhibitor Staurosporine was
from Sigma (St Louis, MO).
Kinase assays were performed using 384-well, white Opti-
plates (Perkin Elmer, Wellsley, MA) in a total volume of
15 µL. Protein Kinase Cα  assays were performed in assay
buffer (20 mM HEPES pH 7.4; 5 mM MgCl2; 0.1 mM
CaCl2, 0.1 mg/ml 1-2-Dioleoyl-sn glycerol (Avanti, Ala-
baster, AL) and 0.02 mg/ml phosphatidylserine (Avanti)
and 0.1% w/v NaN3) using 0.5 µg MBP as substrate for 1
hour at room temperature. The concentration of ATP
(IDC, Livermore, CA) was 10 µM. IRAK4 phosphorylation
was performed in assay buffer containing 50 mM Tris, pH
7.4; 5 mM MgCl2; 1 mM MnCl2; 0.1% BSA and 0.09%
NaN3. The concentration of ATP was 50 µM for enzyme
concentration curves and 10 µM for inhibition experi-
ments. Following the enzymatic reaction, the phosphor-
ylated protein was mixed with 15 µL of QTL Sensor for 10
minutes. Lastly, a rhodamine-labeled phosphorylated
"tracer" peptide was added with a final concentration of
0.5 µM or 125 nM for detection of MBP or Histone H1
and PHAS-1 respectively for 30 minutes at ~25°C. The flu-
orescence of the reaction mixture was measured using a
SpectraMax Gemini XS plate reader (Molecular Devices,
Inc., Sunnyvale, CA) in well scan mode using excitation
wavelength of 450 nm with a 475 nm cutoff filter and
emission readout at 490 nm. Curve fitting was performed
using GraphPad Prism® sigmoid dose-response (variable
slope) software.
List of abbreviations
EC50 = enzyme concentration at 50% of signal; ELISA =
Enzyme linked immunosorbent assay; FP = Fluorescence
polarization; FRET = fluorescence resonance energy trans-
fer; IC50 = Inhibitor concentration that produces 50% of
signal.
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